Eitan Medical Launches UK Operation

January 27, 2021

Eitan Medical, a global leader in advanced infusion therapy and drug delivery solutions has launched a UK operation to improve its support of the SapphireTM infusion pump customers, which include NHS Trusts, private hospitals and homecare providers.

Eitan Medical UK launches with a team of specialists in clinical support, integrated care support, and operations management. The UK entity will be backed by Eitan Medical’s global infrastructure, with offices across Israel, the US, and Europe.

Eitan Medical is the manufacturer of the innovative SapphireTM Infusion Pump as well as the Medtech Breakthrough Award-winning SorrelTM wearable drug delivery platform and has infusion pumps installed across more than 25 countries.

The UK operation, which aims to deliver safe patient-focused infusion solutions that improve healthcare outcomes and quality of life, brings together a team of industry experts with many years of experience in the infusion pump business. The team is reaching out to its existing customers to learn more about their experience so that it can further improve its products and services.

Kean Crispin, Sales Director at Eitan Medical UK, commented: “We’re delighted to be launching our UK operation to improve the support we give to the UK-based clinicians, caregivers and engineers that use our innovative drug delivery and infusion products. By combining our market-proven technology with direct local support for training, repair, accessories, or any other customer needs, we can provide our valued customers with an integrated and holistic service that meets all of their infusion needs.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy